Earnings call slated for October 28th @ 5:30
PM IST / 8:00 AM EDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY) will announce results for the second quarter ended September
30, 2020 on Wednesday, October 28th, 2020 after the Board
Meeting.
Summary of Events
Event
Date and Time
Medium
Release of financial results
October 28th, after the Board Meeting
Stock Exchange, Media, Company website,
Business wire, Email
Press meet presentation
Will be available on the Company’s
website
Company’s website www.drreddys.com
Earnings Call
October 28th, 5:30 PM IST / 8:00 AM
EDT
Hosted by the Company (Details below)
Playback of Earnings Call
After the earnings call till November 4th,
2020
Details below
Transcript of the Earnings call
Will be available on the Company’s
website
Company’s website www.drreddys.com
Earnings Call
Following the release, the management of the Company will host
an earnings call to discuss the Company’s financial performance.
(Dial In and other details given below)
Play Back
The play back will be available after the earnings call, till
November 4th, 2020. For play back dial in phone No: +91 22 7194
5757 | +91 22 6663 5757, and Playback Code is 97779.
Conference Joining Information
Option 1: Express Join with
DiamondPass™
Pre-register with the below link and join without waiting for
the operator.
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=5122677&linkSecurityString=e52c5aa7d
Option 2: Join through below Dial-In
Numbers
Universal Access Number:
+91 22 6280 1219
+91 22 7115 8120
Local Access Number: Available all over
India
+91 70456 71221
International Toll Free Number:
USA: 1 866 746 2133
UK: 0 808 101 1573
Singapore: 800 101 2045
Hong Kong: 800 964 448
No password/pin number is necessary to dial in to any of the
above numbers. The operator will provide instructions on asking
questions before and during the call.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr Reddy’s operates in
markets across the globe. Our Major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues, and (vi) the susceptibility
of our industry and the markets addressed by our, and our
customers’, products and services to economic downturns as a result
of natural disasters, epidemics, pandemics or other widespread
illness, including coronavirus (or COVID-19), and (vii) other risks
and uncertainties identified in our public filings with the
Securities and Exchange Commission, including those listed under
the "Risk Factors" and "Forward-Looking Statements" sections of our
Annual Report on Form 20-F for the year ended March 31, 2020. The
company assumes no obligation to update any information contained
herein.”
The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201012005458/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (Ph:
+91-40-49002135)
MEDIA RELATIONS APARNA TEKURI aparnatekuri@drreddys.com
(PH: +91-40-49002446)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024